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Abstract  Aim: The opinions and attitudes of type 1 (T1) and type 2 (T2) insulin users toward their diagnosis, 
management, treatment and complications as a result of their diabetes were sought. Methods: A bottom-up survey design 
consisting of 66 open and closed questions was used to determine both positive and negative experiences of patients currently 
using insulin by injection only. Results: 707 insulin users (71% T1 and 29% T2) predominately from the UK completed the 
questionnaire. A comparison between T1 and T2 insulin users found that exercise, diet, BG testing and excursions from 
normoglycaemia were the most common source of difficulty amongst these insulin dependent patients. The majority of T1 
participants were found to use a basal bolus insulin regimen (Lantus/Levemir and a short-acting insulin such as Novorapid®, 
Humalog® or Actrapid® but only 34% of T2 insulin users used a similar system with 35% using biphasic insulin aspart 30 
(Novomix®) which may have due to lesser hypoglycaemic events. Conclusions: The results from this survey which focus on 
the common needs of insulin users show that careful follow-up after diagnosis, frequent testing and education about calorie 
turnover from intake and exercise are required for both T1 patients but more so for T2 patients whose needs become similar to 
those of T1 patients once they begin to inject insulin. 
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1. Introduction 
About 366 million people have various common forms of 
diabetes, including lifestyle associated T2 (90% of the total) 
[1], with T1, gestational [2] and other minority diabetic 
conditions such as latent autoimmune diabetes of adults 
(LADA) and maturity onset diabetes of the young (MODY) 
accounting for the rest. This number is expected to rise by 
about 50% in the next 15 years, so that about 10% of the 
world’s population would experience diabetes in one form 
or the other [3]. 
Insulin remains the only effective treatment for 
regulation of glucose levels in T1 diabetes, although 
adjuncts such as anti-hypertensives and statins are now 
included to protect the cardiovascular system from other 
biochemical abnormalities. For T2, the combination of 
dietary control, metformin and sulphonylureas (such as   
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Gliclazide®) are common as a preventive therapy for 
metabolic derangement. Insulin is often added later in the 
progress of T2 disease (or if there has been a heart attack) 
and many authorities believe this is often done too late [4]. 
Diabetes produces changes in the body chemistry that 
lead to the loss of protein function throughout the tissues [5]. 
High blood glucose (BG) concentration glycates 
inappropriately and permanently to the amine groups in 
proteins leading to structural protein and enzyme changes in 
various tissues [6, 7]. Other biochemical dysfunctions and 
compensatory anomalies occur in concert. The result is a 
metabolic derangement of carbohydrate and lipid that 
underpins the development of some of the complications 
that develop in poorly controlled diabetes of either main 
type [8]. These complications are mainly cardiovascular, 
renal, ophthalmic and neurological but also include dental, 
infection-related and wound-healing difficulties all of which 
as expensive to treat. 
The best treatment for maintaining acceptable HbA1c 
values for T1 and T2 diabetes comes from frequent testing 
and insulin doses known as ‘intensive control’ [9]. The 
evidence has been available for more than twenty years but 
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the uptake is far from universal. The methodology is usually 
a combination of calculated background long acting (basal) 
and meal associated insulin boost (short-acting bolus) doses 
and characterised by the variation of dosing to allow a more 
normal diet than previously. The critical thing is to adjust 
frequently during the day to keep BG from chronically 
occurring excursions from normal. The invasiveness of 
injection and finger prick testing could be alleviated by the 
use of an insulin infusion pump and the eventual roll out of 
continuous glucose monitors. Investment in out-patient and 
community support staff, such as diabetes specialist nurses 
(DSNs) and the provision of pumps (much more common in 
the USA) are failure points common to many health 
services not only nationally but globally. The financial 
burden in the UK amounts to £1 million per hour [10, 11] 
which could be reduced by an improvement in the uptake of 
intensive control. Evidence across the world for children 
and adults shows that they fail to achieve optimum HbA1c 
[12]. A fall in HbA1c from 7.9 to 7.0 (63 to 53mmol/mol) 
lowers microvascular risk by 25% which is critical because 
poorly controlled T1 can reduce lifespan by 20 years [12]. 
In this work we present data from responses to a 
questionnaire distributed to T1 and T2 insulin users relating 
to their diagnosis, management, treatment and 
complications as a result of their diabetes. As ~80% of T2 
diabetes patients are treated on oral medications in the UK 
[10] the authors believe this is the first comparison between 
T1 and T2 insulin treated patients. 
2. Method 
2.1. Survey Design, Distribution and Response 
Collection 
A survey of patients with T1 and T2 diabetes who were 
insulin users was carried out. The questionnaires were 
produced in English and distributed to T1 and T2 insulin 
users through various channels. Advertisements were placed 
in various local and national media (such as newspapers) 
within the UK, and in publications from various diabetes 
charities such as Diabetes UK. An interactive web-based 
version of the survey (Survey Monkey®) was also available 
via a dedicated website for participants who wanted to 
submit responses via the internet. The UK Diabetes Network 
and other diabetes websites also distributed copies to 
members on their databases. Finally we used social 
networking sites such Twitter® and Facebook® to publicise 
the survey. 
A total of 707 participants answered 66 questions relating 
to their approach to glucose management, their appreciation 
of its importance and their understanding of the practical 
difficulties of achieving desired control. Responses were 
sought about their attitudes since diagnosis, their medical 
check-ups as well other areas of their management such as 
diet, hypo- and hyperglycaemia and other medical 
conditions.  
2.2. Analysis of Responses 
The responses from Survey Monkey® were downloaded 
in Microsoft Excel 2010® and then coded before inputting 
into Statistical Package for the Social Sciences (SPSS) 
(version 22 “IBM”, Chicago, IL, US). All postal responses 
were entered manually using the same coding directly into 
SPSS®. All data were analysed using (SPSS) and Microsoft 
Excel 2010®. Descriptive statistics, frequencies and 
percentages were calculated to examine the different 
questions and variables in the survey. Data distributions 
were checked for normality and cross tabulations were used 
to investigate the relationship between T1 and T2 insulin 
users. 
3. Results 
3.1. Background Information, Diagnosis and Check-ups 
From the 707 completed surveys, 95% of responses were 
from the UK where the survey was widely distributed and 
advertised with 91.1% of responses from British respondents 
of white ethnicity. The remaining responses were gathered 
from the USA. All respondents were insulin users with 71% 
having T1 diabetes and 29% having T2 diabetes. 42.2% of 
T1 respondents were male compared with 56.9% of T2. 
Respondents were asked how old they were when they left 
full-time education with 19.7% T1 and 44.3% T2 being 16 
years or younger. However, 67.1% of T1 were most likely in 
or had a higher education (e.g. university), compared to 46% 
of T2.  
The most difficult aspect of the diabetes management for 
respondents was found to be exercising (36.6% for T2 and  
34% for T1). Other difficulties were identified as diet, testing 
BG and injecting insulin. About 19.4% of T1 and T2 did not 
report anything difficult about their diabetes. 58.5% of the 
respondents thought that their diabetes was very well 
controlled. 
Respondents were asked where they went for their 
diabetes check-up, the majority (93%) were seen at their 
doctor’s surgery or in a hospital clinic. Respondents were 
also asked to describe the amount of written and verbal 
information they received when they were first diagnosed 
with diabetes. For verbal, 3% of T1 and 7.3% of T2 did not 
receive any information, 27.1% of T1, 31.7% of T2 received 
too little information and 44.6% of T1, 52.2% of T2 received 
the right amount of information. However, for written help, 
8.8% of T1 and 14.6% of T2 did not receive any (such as 
leaflets or information booklets), 25.3% of T1, 22.4% of T2 
too little information and the right amount of information 
was received by 32.5% of T1, 40.5% of T2. Of these, 2.8% 
of T1 and 2.0% of T2 had not had a diabetes check-up in the 
last 12 months, 30.9% of T1, 24% of T2 had one, 40% of T1, 
49.5% of T2 had two and 26.2% of T1, 24.5% of T2 had had 
three or more check-ups. 
In the last 12 months, 69% of T1 and T2 had an 
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opportunity most of the time to discuss their ideas about the 
best way to manage their diabetes with their medical 
advisors. However, a high proportion, 38.8% of T1 and  
37.9% of T2 had no chance or rarely discussed possible 
different medications. In addition to this, 41.5% of T1 and 
35.1% of T2 had rarely or never had personal advice about 
the kinds of food to eat and 43.5% of T1, 37% of T2 received 
similarly little personal advice about their levels of physical 
activity.  
More than half of the respondents (50.7% T1 and 56.7% 
T2) reported that they always or mostly had a plan to manage 
their diabetes over the next 12 months with their medical 
advisors. The majority of all respondents (95%) had had a 
HbA1c test, blood pressure measurement and their weight 
checked by a doctor or nurse in the previous 12 months as 
part of their treatment. Also in the past 12 months over   
72.3% of T1 and T2 respondents had their cholesterol, eyes 
and bare feet examined. 36.3% of T1 and 26.3% of T2 had 
also talked to a dietician in the previous 12 months about 
their dietary management. When T1 and T2 respondents 
were asked if they had stayed in hospital overnight as a 
patient in the last 12 months, 19% of T1 and T2 reported that 
they had. Of those respondents 65.2% of T1 and 56.4% of T2 
had stayed for 1 – 3 nights, with 43.7% of T1 and 17.9 of T2 
reporting that the reason was diabetes related. 
3.2. Management and Diet 
Table 1 shows the types of insulin used by T1 and T2 
respondents. 
It should be noted that respondents were asked to tick all 
insulins they used and all respondents that injected Lantus® 
or Levemir® also used a short acting insulin such as 
Novorapid® (54.5% for T1 and 24% for T2), Humalog® 
(17.7% for T1 and 9.3% for T2) and Actrapid® (3% for T1 
and 0.5% for T2). 13.6% of T2 respondents also used 
Novomix® and 22.9% used other insulins not listed in the 
survey responses and shown in Table 1. Most of T1 77.6% 
and more than half of T2 53.6% started using insulin longer 
than 5 years ago. 
86.4% of T1 and 39.5% of T2 gave themselves 4 or more 
daily injections. 42.1% T2 gave themselves 2 injections 
compared with only 8.4% of T1. 21.2% of T1 and  36.7% of 
T2 have been using the same number of injections since they 
started taking insulin and 45.1% of T1 compared with 21.3% 
of T2 have using the same regimen for 5 years or longer.  
72.3% of T1 and 82% of T2 described the total amount of 
insulin they used for the previous 24 hours as more than 30 
units. 
The majority of T1 (65%) and 22.6% of T2 tested their 
blood glucose 4 or more times a day. About half of T2 
(49.2%) tested it once to three times a day compared to  
27.6% of T1. Respondents in this survey used the results of 
their BG tests to check or alter the amount of insulin they 
take (87.5% of T1 and 57.1% of T2). A further 72.7% of T1, 
48.8% of T2 used BG tests to warn them about impending 
hypoglycaemic episodes. More than 79% of T1 and T2 
respondents knew their HbA1c result and what that result 
meant. 
Table 1.  Types of Insulins Used By T1 and T2 Respondents 
Type of Insulin T1 T2 
Actrapid® 1.4% 0.5% 
Humalog® 4.8% 4.8% 
Humulin l® 2.8% 2.9% 
Humulin M® 0.4% 2.9% 
Humulin S® 0.6% 0.5% 
Hypurin® 0.6% 1.5% 
Insulotard® 4.8% 5.4% 
Mixtard® 1% 3.4% 
Novorapid® 7.1% 4.8% 
Novomix® 3.6% 13.6% 
Other 3.4% 22.4% 
Combination of Insulins Selected 
Lantus®/Levemir® + Novorapid® 54.5% 24.0% 
Lantus®/Levemir® + Humalog® 17.7% 9.3% 
Lantus®/Levemir® + Actrapid® 3% 0.5% 
Lantus®/Levemir® + Humulin I® 0.6% 0.5% 
Lantus®/Levemir® + Mixtard® 1% 0% 
Lantus®/Levemir® + Insulotard® 0.6% 0.5% 
Lantus®/Levemir® + Novomix® 0% 0.5% 
Lantus®/Levemir® + Other 0.2% 0.5% 
Lantus®/Levemir® + Humulin S® 0.6% 0.5% 
Table 2 outlines the amount of information respondents 
were given relating to the management of their diabetes. In 
terms of a healthy lifestyle and calorie balance, 71% of T1 
and 58.1% of T2 found eating the right foods to help them 
manage their diabetes was easy, however, 29% of T1 and 
41.9% of T2 found it difficult. More than 81% of T1 and T2 
had been given dietary advice to help control their diabetes 
with 30.3% of T1 and 30.1% of T2 describing their daily 
calories consumed as between 1500 – 2000. 36.8% of T1 and 
28.4% of T2 did not know their daily calorific consumption. 
79.8% of T1 and only 32.2% of T2 respondents have been 
given information to help them to count carbohydrates. 68% 
of T1 compared with only 19.3% of T2 counted 
carbohydrates regularly in order to help them to control their 
diabetes. In addition, more than half of T1 (50.8%) and only 
minority (7.5%) of T2 used DAFNE to calculate or count 
carbohydrates. 
When questioned about exercise habits, 44.2% with T1 
and 37.1% of those with T2 did between 1 and 3 hours of 
exercise per week, 32.1% of T1 and 24.4% of T2 participated 
in more than 3 hours of exercise. However, 11.1% of T1 and 
17.8% of T2 did not do any exercise. Only 30.1% of T1 and 
17.6% of T2 found BG results helpful in deciding how much 
physical activity they should do. 
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With regards to respondents general health, 65.6% of T1 
and 58.2% of T2 described their health since discovering 
they had diabetes as good, but 16.5% of T1 and 31.1% of T2 
said their health remained poor since diagnosis of their 
diabetes. More than half of the respondents described 
diabetes as affecting their day-to-day activities and only  
5.6% of T1 and 8.2% of T2 found it did not affect their 
activities at all. 








T1D T2D T1D T2D T1D T2D 
How to manage your diabetes when you are ill, e.g. having flu. 0.0% 0.0% 71.1% 51.7% 24.3% 42.0% 
Getting to and keeping to a certain weight 0.8% 1% 53.6% 59.5% 39% 32.7% 
What to expect if your blood glucose drops too low or becomes high. 2.2% 0.5% 84.9% 74.6% 8.2% 19.5% 
The reasons for taking prescribed medicines to manage your diabetes. 2.0% 1% 80.9% 76.6% 9.6% 15.1% 
The long term health effects of your diabetes. 7.8% 3.9% 69.9% 69.8% 17.5% 21% 
The importance of raised cholesterol levels for people with diabetes 1.4% 0.5% 55.4% 66.3% 38.2% 27.8% 
The importance of high blood pressure in people with diabetes 0.8% 1.5% 59.4% 67.8% 34.5% 24.9% 
The importance of regular eye checks for people with diabetes 2.6% 1.5% 87.8% 88.3% 5.2% 5.4% 
The importance of checking and looking after your feet 1.6% 2% 77.7% 80% 16.3% 13.7% 
How drinking alcohol can affect your diabetes 1.8% 2.9% 66.7% 66.8% 25.3% 21.5% 
How smoking can affect people with diabetes 2.4% 2.4% 72.3% 70.7% 17.5% 17.1% 
The effects of stress on your diabetes 0.8% 0.0% 39.2% 40.5% 54.4% 53.2% 
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3.3. Hypoglycaemia 
The vast majority of respondents had experienced 
hypoglycaemia at some time since diagnosis (98.9% T1 and 
86.1% T2), however, the majority of these respondents did 
not experience black out, convulsions/fit and coma when this 
occurred. Nevertheless, they experienced the following 
symptoms: paleness (45% of T1 and 22.4% of T2), trembling 
(64.7% of T1 and 56.1% of T2) , sweating (76.9% of T1 and 
62% of T2), feeling of weakness (76.3% of T1 and 65.4% of 
T2), rapid heartbeat (37.6% of T1 and 22.4% of T2), hunger 
(49.2% of T1 and 25.9% of T2), agitation/irritability (69.5% 
of T1 and 34.6% of T2), poor concentration (68.9% of T1 
and  46.3% of T2), blurred vision (43% of T1 and 23.4% of 
T2) and loss of coherence (45.2% of T1 and 21.5% of T2). In 
general, the survey found that people with T1 diabetes have 
experienced these symptoms more than T2. 
About 67% of T1 and T2 felt hypoglycaemic symptoms 
when their BG level was between 3 and 4 mmol/L. However, 
6.3% of T1 and 19.9% of T2 felt similar symptoms between 
4 and 5 mmol/L while 26.4% of T1 and 13.7% of T2 only felt 
symptoms below 3 mmol/L. 21.6% of T1 and 11% of T2 
stated that hypoglycaemia affected their day-to-day activities 
quite a lot or great deal. However, 77.5% of T1 and 89% of 
T2 described little or no effect. Most of the respondents in 
this survey (93.2% of T1 and 76.1% of T2) responded to a 
low BG by taking a sugary food or drink immediately. 
About 14.3% of T1 and 8.4% of T2 had decided whether 
or not to drive, either on occasion or permanently due to 
problems with low BG. 29.6% of T1 and 20.1% of T2 had 
had “severe” hypoglycaemic episodes during the past 12 
months with 52.4% of T1 and 61.8% of T2 having severe 
symptoms once or twice. 25.2% of T1 and 17.6% of T2 had it 
three to five times and 22.4% of T1 and 20.6% of T2 had it 
six times or more. During a12 month period, 16.3% of T1 
and 6.5% of T2 had passed out or had a seizure because of 
low blood sugar and required help from others. Most of them 
(73.3% of T1 and 81.8% of T2) had this once or two times, 
12% of T1 and 9.1% of T2 had it three to five times and  
14.7% of T1 and 9.1% of T2 had it six times or more. When 
respondents were asked when their last “severe” low blood 
sugar episode happened, 55.3% of T1 and 43.2% of T2 
reported that it happened longer than 6 months ago and  
24.8% of T1 and 33.3% of T2 said that they had it within the 
last month. 4.5% of T1 and 4.6% of T2 reported they had to 
go to hospital because of their hypoglycaemic episode.  
3.4. Hyperglycaemia 
When respondents were asked if their BG had ever been 
above 20mmol/L, 84.2% of T1 and 57.5% of T2 replied 
positively. About 63.2% of T1 and 46.7% of T2 said they 
could sense when their BG was above 13mmol/L without 
testing. Interestingly, however, 31% of T1 and 33.8% of T2 
had found their BG 13mmol/L or above once or twice a week. 
59.2% of T1 and 33.1% of T2 had more than twice a week. 
Only a third, (33.1%) of T2 and 9.8% of T1 had never 
reported a BG as high as 13mmol/L or above, but despite the 
tendency to hyperglycaemia, 93.2% of T1 and 97.1% of T2 
had never been in a coma because of high BG. When 
respondents were asked what triggered their high blood 
sugar (13mmol/L or above), 36.5% of T1 and 16.6% of T2 
said it was due to a missed insulin injection. 27.1% of T1 and 
25.9% of T2 mentioned the trigger was an illness or due to 
physiological stress such as infection.  
3.5. Other Medical Conditions and Complications 
28.3% of those with T1 and 26.7% of T2 were hospitalised 
several times. Table 3 shows a summary of responses from 
both T1 and T2 respondents relating to other medical 
conditions diagnosed or symptoms tested for. 57.6% of T2 
and 32.7%T1 had been told that they had high blood pressure 
(BP) and 34.6% of T2 and 17.3% of T1 monitored their BP at 
home. When asked about BP medication, 60% of T2 and a 
quarter of T1 said that they took it. When respondents were 
questioned about other complications, 10.2% and 18.5% of 
T2 had had a heart attack or chest pain/pressure (angina), 
respectively, only 2% and 4.6% of T1 had these 
complications. Stroke was suspected or experienced by  
12.2% of T2 and 3.4% of T1. 
4. Discussion  
In the UK the prevalence of T2 diabetes in comparison to 
T1 is approximately 9 to 1 respectively [10]. The causes of 
T2 diabetes are often attributed to patients being overweight 
or obese and the first line of treatment are usually oral 
medications (sulfonylureas and Metformin®) and lifestyle 
changes such as more frequent exercise and improvements in 
dietary control. Once these changes have been implemented 
and the patient still maintains abnormal BG and HbA1c 
readings suggesting that they no longer maintain 
normoglycaemia as a result of factors such loss of insulin 
receptor sensitivity and beta cell deterioration, insulin is 
introduced. Symptoms of T2 diabetes usually present in 
people who are over 25 years of age although the highest 
prevalence are in patients over 60 years of age [13]. In this 
work we provide a comparison by means of a questionnaire 
between insulin users with T1 and T2 diabetes to assess how 
they have essentially managed and treated their diabetes. 
Most of the responses gathered in this survey were from 
patients with T1 diabetes which usually presents in people 
under the age of 40 with the majority of cases occur in 
juveniles. As these patients are generally younger than most 
T2 patients and they have to inject insulin daily in order to 
survive, they may respond more enthusiastically to 
questionnaires. There was a greater proportion of T1 than T2 
respondents having received a higher education and this may 
underpin a keenness for learning more about their condition 
and engaging in research initiatives. It may be important 
when recruiting for surveys to think about the font size and 
other aspects of visual clarity, so that those with poor or 
ageing eyesight are not excluded. 
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Table 3.  Medical Conditions or Symptoms Experienced By Respondents 
 T1 T2 
Have you ever seen a specialist eye doctor (ophthalmologist)? 64.5% 61% 
Has your eyesight suffered as a consequence of your diabetes? 36.3% 37.6% 
Have you been diagnosed with retinopathy (decrease in visual acuity)? 20.7% 22.0% 
Have you been diagnosed with diabetic macular oedema (blurred vision)? 3.2% 4.9% 
Have you ever been told that you have protein in your urine? 30.3% 36.6% 
Do you have your blood creatinine checked? 48.8% 45.9% 
Do you have diabetic kidney disease? 3.8% 4.9% 
Do you require dialysis? 1.0% 1.0% 
Have you had a kidney transplant? 1.0% 0% 
Is your usual blood pressure normal? 74.3% 50.2% 
Have you ever been told you have high blood pressure 32.7% 57.6% 
Do you monitor your own blood pressure (BP) at home? 17.3% 34.6% 
Do you take medication for high blood pressure? 24.1% 60.0% 
Are you on lipid lowering medication (for high cholesterol or triglycerides)? 32.1% 58.5% 
Have you ever had a heart attack? 2.0% 10.2% 
Do you ever have chest pain or pressure (angina)? 4.6% 18.5% 
Have you ever had a cardiac catheterisation? 2.6% 6.8% 
Have you ever had heart bypass surgery (coronary artery bypass)? 1.2% 7.3% 
Have you ever had a balloon angioplasty or a coronary stent placed? 1.6% 5.9% 
Have you ever had, or suspected that you had a stroke? 3.4% 12.2% 
Other symptoms experienced 
Numbness or tingling of extremities 31.7% 55.6% 
Burning or pain in feet 14.9% 35.1% 
Decreased sensation to a body part 10.8% 27.3% 
Foot deformity 1.4% 7.8% 
Loss of sensation to a body part or area 7.0% 20.0% 
Diagnosed with diabetic neuropathy 8.0% 22.9% 
Foot ulcers 2.4% 7.3% 
 
In 2007 the largest survey ever conducted by the 
Healthcare Commission’s National Patient Experience 
Survey Programme [13], which included 152 Primary Care 
Trusts (PCT) across England collected responses from 
68501 questionnaires (a response rate of 55%), where 87% 
of the respondents were T2 and 13% T1. Of those 
respondents 96% T1 and 17% T2 (25% of the total 68501 
respondents) were insulin users in the same way as those 
participating in this survey. They found that 73% of all 
respondents received the right amount of verbal information, 
compared with 57% of all respondents when it came to 
written information at the time of diagnosis. They also found 
that those patients diagnosed with diabetes in the last five 
years were more likely to receive the right amount of written 
and verbal information. Although the Healthcare 
Commission’s findings [13] were from all respondents in the 
survey (so include T2 tablet users as well as others) their 
results suggest that there is a lack of information provided 
across the whole spectrum of people diagnosed with diabetes 
in terms of information to allow self-management effectively. 
The results in this work show that the provision for verbal 
information at the time of diagnosis was similar or better 
than for written information to the Healthcare Commission’s 
[13], 70% of T1 and 61% T2 received at least the right 
amount of verbal information and 65.9% T1 and 61% 
received at least the right amount of written information at 
diagnosis. These results show that well targeted information 
in both forms seems a prerequisite for managing patients on 
insulin. 
Respondents were asked where they went for their 
diabetes check-up, 22.6% of T1 and 52.1% T2 were seen in 
their doctor’s surgery, 70.2% of T1 and 41.7% were seen at a 
hospital clinic. The Healthcare Commission survey [13] 
found that 85% of T2 diabetes patients had their check-up at 
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their doctors surgery, with only 13% attending a hospital 
clinic, whereas those with T1 diabetes had a check-up in a 
hospital clinic (63%) and 32% at their GP’s surgery. These 
findings would incorporate T2 diabetes patients who were 
controlling their diabetes by tablet so were not so perhaps did 
not need more specialised diabetes clinics. However, the T2 
patients in this survey were insulin users similar to those that 
are T1 yet 52.1% (T2) versus 22.6% T1 were still seen by 
their GP suggesting that despite injecting insulin they were 
not checked in hospital clinics. 
The results from this survey correlate well with those 
found in the Healthcare Commission’s report [13] which 
showed that in the 12 months prior to answering their 
questionnaire 98% of the respondents had had their blood 
pressure measured, 91% HbA1c and weight, 89% cholesterol, 
87% a urine test for protein, 83% their bare feet examined 
and finally only 23% reported seeing a dietician within the 
last 12 months. In the UK these tests form the basis of NICE 
guidelines for the nine care processes which diabetes patients 
should undergo, yet the National Diabetes Audit results for 
2009/10 [14] showed that throughout the UK two-thirds of 
adults with T1 diabetes, and half of people with T2 diabetes 
fail to get these annual tests and investigations that are 
recommended in the national standards [14]. This survey 
found that for people with T2 diabetes the most difficult 
aspect of their diabetes management was found to be 
exercise. This was reflected in responses where 44.2% T1 
and 37.1% T2 participated between one and three hours of 
exercise per week and 11.1% of T1 and 17.8% T2 
respondents did not perform any exercise. T2 diabetes is 
often associated with lifestyle and in most cases can be 
related to lack of exercise and obesity. It was noticeable that 
the number of responses didn’t participate in any exercise 
was greater from people with T2 diabetes. This may have 
been influenced by the age of the T2 respondents who 
present diabetes symptoms in later life and they may also 
have other medical conditions which prevent participation in 
exercise. 
Diet was also identified by respondents as a source of 
difficulty for their diabetes with 29% of T1 finding difficult 
to find the right foods to manage their diabetes compared 
with 41.9% T2 insulin users. This is despite 51% T1 using an 
educational DAFNE programme and over 81% of all 
respondents receiving some dietary advice since diagnosis 
from their medical advisors [15] found that patients with T1 
using MDI therapy often underestimated their carbohydrate 
intake by 20% and this was usually a result of anticipated 
exercise or fear of hypoglycaemia as a result of their injected 
insulin. Paradoxically, T1 patients who don’t have access to 
well-structured education may be systematically 
over-insulinised. Both these findings add to the growing 
body of evidence for the benefits of the DAFNE programme 
[16, 17]. A judicious and targeted insulin therapy following 
DAFNE training in T1 has been found to allow patients to 
achieve better glycaemic targets with less insulin [16]. 
Despite this only 7.2% of T2 respondents were using 
DAFNE and 50.8% of these T2 respondents counted their 
carbohydrates, suggesting that structured education 
programmes such as DAFNE for T2 insulin users were much 
less frequently used.  
The frequency of BG testing was higher in T1 insulin 
users with 65% T1 testing 4 or more times which correlates 
with 86.4% of T1 injecting insulin 4 or more times 
suggesting that respondents may have been injecting prior to 
calorie intake with a short-acting insulin such as 
Novorapid® or Humalog®. Table 1 showed that most T1 
and T2 respondents were using Lantus®/Levemir® and in 
order to see if these respondents were on a basal bolus insulin 
regimen a cross tabulation of the data was performed with 
the short-acting insulins Novorapid®, Humalog® and 
Actrapid®. The data in Table 1 revealed all the insulins 
respondents were using so more than one option may have 
been ticked and for T1 respondents there were responses 
received which included more than two insulins but these 
were less than 1% of total T1 responses and have therefore 
not been separated out in Table 1. The data in Table 1 
suggests that most T1 respondents (~75%) were using the 
long acting insulin (Lantus® or Levemir®) in combination 
with a short-acting insulin such as Novorapid®, Humalog® 
and Actrapid® and as such were using a basal bolus system. 
This was not the case for T2 respondents (~34%) were using 
the same basal bolus system and ~35% using Novomix® and 
other insulins not listed in the survey. In order to use a basal 
bolus insulin regimen the patient would have to test their BG 
prior to calorie intake and bolus accordingly which provides 
a more intensive BG control and would prevent hypo- and 
hyperglycaemia.[18] found that T2 patients using a basal 
bolus system have found that the number of injections per 
day and more frequent hypoglycaemic episodes difficult and 
report that after 24 weeks T2 patients switching from 
basal-bolus insulin regimens to biphasic insulin aspart 30 
(Novomix®), glycaemic control and health related quality of 
life were significantly improved, and hypoglycaemia was 
significantly reduced. This may account for the higher 
number of T2 respondents using Novomix® in this survey. 
Differences in the testing of BG were found for T2 insulin 
users in this work compared to those of the Healthcare 
Commission [13] where 31% with T1 diabetes tested 4 or 
more with only 3% of T2. Similarly, only 4% with T1 never 
monitored their BG compared with 29% T2. This could be 
attributed to the greater number of participants taking part in 
the Healthcare Commission survey which was able to 
capture data over a broader range of patients with diabetes 
who may have been treating there diabetes with oral 
medications. 
Both T1 and T2 patients had experienced hypoglycaemia 
indicating that they their current treatment by insulin 
injection allowed them drift lower than normoglycaemia. 
Although most of these respondents did not exhibit serious 
symptoms such as black out or coma they did experience 
more typical conditions such as trembling and weakness. 
Agitation and poor concentration were felt by more T1 
respondents. Most T1 and T2 respondents felt these 
symptoms when their BG was between 3-4mmol/L. Defining 
 
20 Joan Taylor et al.:  A Survey Comparing the Management of Diabetes, Hypoglycaemia   
and Hyperglycaemia by Type 1 and Type 2 Insulin Users 
BG values for hypoglycaemia remains difficult with 
surgeons and forensic pathologists defining spontaneous 
pathological hypoglycaemia requiring investigation and 
treatment at BG < 2.2 mmol/L, to avoid defining healthy 
people as hypoglycaemic[19]. At the other extreme, the 
American Diabetes Association (ADA) [20] defined BG 
concentrations of < 3.9 mmol/L as hypoglycaemia, based on 
the reduction in endogenous insulin and increase in 
pancreatic glucagon which can be demonstrated at this level. 
However, defining hypoglycaemia < 3.9 mmol/L could lead 
to overestimation of clinically significant hypoglycaemia 
associated with any specific diabetes therapy. The European 
Medicines Agency [21] recommend a value of < 3.0 mmol/L 
when assessing hypoglycaemic risk of different treatment 
regimens. Impaired cognitive function is seen at plasma BG 
concentrations of < 3.0 mmol/L and avoidance of plasma BG 
concentrations of < 3.0 mmol/L has been able to restore 
hypoglycaemia awareness to people with T1 diabetes and 
defective counter regulation. As insulin-deficient patients 
with diabetes lose their ability to modulate either insulin or 
glucagon in response to hypoglycaemia and depend instead 
on autonomic activation, subjective awareness and 
adrenaline to defend against severe hypoglycaemia. Risk 
factors for individual episodes of hypoglycaemia in patients 
with T2 diabetes include behavioural, physiological and 
therapeutic factors, the most common behavioural factor 
being identified as missed or irregular meals. Other lifestyle 
factors include alcohol, exercise and incorrect use of 
glucose-lowering medication (dose/timing). 
Hyperglycaemia causes vascular risks such as 
hypertension and cerobropetal arteries increasing the chance 
of strokes taking place is twice as much in patients with 
diabetes [22]. The present survey shows that 63.2% of T1 
respondents thought that they could sense when their BG 
was above 13mmol/L yet that dyslipidaemia as well as 
atherosclerotic changes in the heart and over 90% of T1 
respondents had these above normal BG reading once or 
more a week. Similarly for T2 respondents, 46.7% could 
sense an above normal BG with 68% have these high BG 
episodes more than once a week. 33% of T1 respondents had 
suffered from diabetic ketoacidosis (DKA) and most of these 
had been hospitalised as a result indicating that the treatment 
and management of respondents was clearly not adequate to 
maintain BG control, similar trends were observed for T2 
respondents. It is likely that the DKA episodes reported by 
T1 respondents will have included those that were reported 
at the time of diagnosis. 
The Diabetes Control and Complications Trial (DCCT) 
showed that 1422 patients with T1 diabetes who were treated 
with intensive control of BG concentrations for 6.5 years had 
a 57% reduced risk of cardiovascular events over a means 
follow up period of 17 years compared with individuals on 
conventional treatment [23]. These trials suggest that the 
balance of recurrent hypoglycaemia against the advantages 
of a low HbA1c value should consider factors such as the 
patient’s age, duration of diabetes and comorbidities. The 
results from this survey which focus on the common needs of 
insulin users show that careful follow-up after diagnosis, 
frequent testing and education about calorie turnover from 
intake and exercise are required for both T1 patients but 
more so for T2 patients whose needs become similar to those 
of T1 patients once they begin to inject insulin. Although 
these T2 insulin patients are often older than T1 insulin users 
who are often children at time of diagnosis the same 
resources should be made available in terms of management 
and treatment of their diabetes. The HbA1c value forms an 
important part of a diabetes patient’s management and 
subsequent treatment and as insulin is a potent drug the 
possibility of hypoglycaemia is always present. Treatments 
should therefore include judicious and frequent testing with a 
basal bolus insulin regimen. For T2 patients who struggle 
with BG management and frequent hyperglycaemia the 
introduction of insulin injections should also be much earlier 
before cumulative effects of complications make the patient 
too ill to really benefit. 
5. Conclusions 
Aside from the serious personal consequences, the cost of 
diabetes and its complications has been variously quoted as 
5-10% of the UK NHS budget [10], depending on the costing 
criteria and a recent report quotes this as equating to about 
£1m/h. The results from this study show that current 
treatment and management of diabetes care still poses 
difficulty for most patients and that for T1 and T2 diabetes 
patients further improvement is required. 
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